Cancer Research UK
Dear Prime Minister: England is facing a cancer emergency
One Cancer Voice is a group of over 60 cancer charities, collectively supporting millions of people living with cancer.
We want the Prime Minister to commit to taking action to dramatically improve the experience and outcomes of people affected by cancer. We have come together to call on the UK Government to put the needs of cancer patients first by:
- Ensuring the upcoming Major Conditions Strategy is ambitious, fully-funded and listens to the voices and evidence of the cancer community.
- Committing to a longer-term strategy for cancer which focusses on transforming cancer research, diagnosis, treatment and patient experience.
- Please Click Here to take you to Cancer Research to add your name to the petition.
The impact of cancer on people in the UK is set to grow, according to our latest report. (Feb23)
New modelling in the report shows that if current trends continue, cancer diagnoses will rise from around 400,000 per year today to over 500,000 by 2040. This is mainly due to the growing and ageing population.
However, there are opportunities to improve how we prevent cancer, reduce late-stage diagnosis and provide better treatment options, but these changes won’t implement themselves. It is more important than ever that each UK nation set out its plan of action to improve how they tackle cancer. The Government needs to provide long-term, lasting solutions.
That’s why we’re asking Rishi Sunak to commit to an ambitious, focused and fully costed long-term strategy for cancer that will prepare cancer services for the future and give people affected by cancer the care they deserve.
Please click here to read more ……
Research Media News
New tool will 'tailor cancer care in the next five years'
Cancer patients to be given vaccine trials by autumn
Government signs deal with BioNTech to test therapies using same technology as its world-leading Covid jabs
JOE PINKSTONE Science Correspondent Telegraph 7th January 2023.
CANCER vaccine trials will start in the UK this year after the Government signed a deal with BioNTech, the company that created the mRNA technology behind the Pfizer Covid jab. The agreement will enable BioNTech to conduct cutting-edge clinical trials in the UK with British patients set to be enrolled in trials as soon as this autumn.
The so-called cancer vaccines are not preventative but are instead therapeutic tools designed to fight established disease and advanced tumours.
BioNTech created the world’s first authorised mRNA vaccine for the coronavirus in 2020. It works by injecting a person with a small piece of genetic code to create a specific immune response. It was found to be safe and extremely effective at protecting against severe disease from Covid-19, and updated omicron-specific jabs are now being rolled out to over-50s.
Britain was the first country to give people the BioNTech vaccine as a result of the rapid approval from the MHRA, recommendation from the JCVI and distribution by the NHS.
These pandemic-forged relationships have led to the company investing money to conduct mRNA vaccine research in Britain. It is understood that a lab of around 70 scientists will be created in Cambridge to spearhead the research while the firm will also set up a London-based office as its UK headquarters.
The offices and labs will be ready to start in the coming weeks and months ahead of people being enrolled in cancer vaccine trials by September. Patients will be recruited by the company for the trials via the Cancer Vaccine Launch Pad, which is being created by the NHS and Genomics England, and will help researchers find ideal candidates for various drugs. Multiple forms of cancer, including breast, lung and pancreatic, will be targeted by BioNTech’s vaccine technology, as well as Covid, malaria and TB.
It is hoped that the technology will be found to be safe and effective, embedded into standard care and that 10,000 doses will be given to UK patients by 2030. The announcement of the BioNTech agreement comes less than a month after it was confirmed that the UK had signed a deal with the world’s other premier mRNA medicines manufacturer, Moderna, to make mRNA vaccines in the UK.
The two contracts ally Britain with the world’s two most prominent mRNA vaccine companies in the world and will ensure access for Britons to breakthrough immunisations and treatments.
Steve Barclay, the Health Secretary, said: “This partnership will mean that, from as early as September, our patients will be among the first to participate in trials and tests to provide targeted, personalised and precision treatments using transformative new therapies
New tool will 'tailor cancer care in the next five years'
DNA pattern discovery will immediately change how we treat disease and paves way for bespoke therapy
Article in Daily Telegraph 22nd April 2022 By Laura Donnelly HEALTH EDITOR
DNA Pattern Discovery
CANCER treatment is set to be revolutionised by a “mindblowing” gene study by the University of Cambridge, which has discovered 58 mutational signatures, experts say. The findings, from the largest study of its kind, will allow medics to provide more personalised treatment, matched to individual tumours.
Until now, scientists had identified 72 mutational signatures that could cause cancer. But the new research – based on tumours from more than 12,000 NHS patients – has found “a treasure trove” of new clues that will allow medics to develop a tool to help match treatments to patients.
Scientists behind the study said the technique can be used immediately on any patient who undergoes whole-genome sequencing. Currently, this is largely offered to those with rare diseases and inherited disorders, as well as all children with cancer.
But there are plans to roll this out far more widely in the next five to 10 years.
A team of scientists led by Prof Serena Nik-Zainal, from Cambridge University Hospitals and University of Cambridge, said the scale of the study, and the vast amount of data, meant they could detect patterns in the DNA of cancer that had never been identified before. The research, supported by Cancer Research UK, published in the journal Science, has allowed scientists to develop a computer-based tool that means that any cancer patient who undergoes whole-genome sequencing can be checked for the signatures, and given tailored treatment advice.
It means they could be offered types of immunotherapy that only work on particular tumours, for example.
Prof Nik-Zainal, professor of genomic medicine and bioinformatics, said it was “mindblowing” to have been able to carry out such major research involving so many patients.
She added: “I’m amazed. I am so proud, actually, to be a doctor and a scientist that can use this data that has been generated by the public sector; it is extraordinary.”
She said the research was a “really important step forward” in the use of genomics as a standardised test for the future. “The reason it is important to identify mutational signatures is because they are like fingerprints at a crime scene – they help to pinpoint cancer culprits,” she added.
“It’s like looking at a very busy beach with thousands of footprints in the sand. To the untrained eye, the footprints appear to be random and meaningless. But if you are able to study them closely, you can learn a lot about what’s been going on, distinguish between animal and human prints, how old the prints are, whether it’s an adult or child, what direction they’re travelling in,” the scientist said.
“It’s the same thing with the mutational signatures. The use of whole-genome sequencing can identify which ‘footprints’ are relevant and important and reveal what’s happened through the development of the cancer.”
The data were provided by the 100,000 Genomes Project, an England-wide research initiative to sequence 100,000 whole genomes from 85,000 patients affected by rare disease or cancer.
Simple Blood Test 'could give us mastery over cancer'
Firm behind process that can identify 70 types of the disease hopes it could be rolled out across NHS
LAURA DONNELLY Health Editor Daily Telegraph 29th October 2022
A SIMPLE blood test could give mankind “mastery over cancer” by spotting nearly every case before it spreads, scientists say.
The technology – which can identify 70 types of cancer – is currently being offered privately, with the company behind it keen for it to be rolled out across the NHS.
Scientists say such techniques could be introduced as standard screening within the next five to 10 years, allowing medics to eradicate cancer long before symptoms are present.
Research on 30,000 people found the checks could identify 91.8 per cent of cases which were non-metastatic.
This meant it was more treatable, because it had not spread beyond the primary site where it was found.
The NHS is already running the largest ever trial of blood tests to screen for cancer, involving 140,000 people, with hopes it could prevent one in 10 cancer deaths.
So far, studies have found that the Galleri test, which can detect at least 50 types of cancer, is able to detect more than half of the cases of disease.
But a British not-for-profit company believes that a different type of “liquid biopsy”, called Trucheck, could prove superior – especially at detecting cases at the earliest stages, when they are most treatable.
The tests were able to detect nine in 10 cases of cancer whether or not it was metastatic.
By contrast, the Galleri test reached similar levels of performance when cancer had reached stage four, meaning disease was advanced and may be terminal.
The Trucheck test is now being offered to private customers by British not-for-profit organisation the Cancer Screening Trust, at a cost of £1,100, including a consultation.
The company is also in talks with NHS cancer networks, about running further trials, in the hope it could be rolled out in the health service.
‘I think this is genuinely going to change the way cancer is thought about and the way it’s treated’
Joe Coles, chairman of the Cancer Screening Trust, said: “I genuinely think this is game-changing. It’s going to change the way cancer is thought about and treated.”
Experts said the beauty of the technology was in identifying cases early.
The blood test itself takes less than a minute, involving just two 10ml vials..
The Trucheck test, developed by the Indian firm Datar Cancer Genetics, is also available elsewhere, including in the United States and Germany.
Studies of Galleri, a test developed by the company Grail, which is now being piloted across the NHS – have found that at stage 1 it was able to detect 16.8 per cent of cases, rising to 40.4 per cent at stage 2, 77 per cent at stage 3 and 90.1 per cent at stage four.
By contrast, the Trucheck test was able to spot 91.8 per cent of cases which were non-metastatic, research published in Cancer Cytology found. It also found 92.6 per cent of cases where disease had spread beyond the primary site.
Even at stage three, cancer can remain “non-metastatic” and the study of Trucheck did not show how many cases were picked up at this stage, rather than at stages one or two, when it is most amenable to treatment.
However, separate studies on breast cancer found the new technology was able to identify almost nine in 10 cases at stage one, while Galleri picked up around 16 per cent of cases.
A spokesman for Grail said latest trial results for Galleri, showing it found cancer in about one per cent of participants – including types for which there is no established screening method – “further strengthened confidence” in its ability to accurately detect cases.
Through social & virtual events, such as our Wellbeing Webinars, where everyone can meet, chat and seek advice. We have now returned to "real" social gatherings.
Click here for ~ Newsletters
As well as running educational events, we have a website where lots of information about Melanoma, will be easily accessible and pooled into one simple point of access.